News
EQS-News: Neue Direktorin für die Hotelbusiness Zug AG
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
EQS-News: Swiss Re ernennt Pravina Ladva zum Group Chief Digital & Technology Officer und reorganisiert Group Operations
EQS-News: Swiss Re appoints Pravina Ladva as Group Chief Digital & Technology Officer and reorganises Group Operations
EQS-News: Norwegian Film Institute Expands Availability and Boosts Global Demand for Norwegian Films with NAGRA Technology
EQS-News: Swiss Re Institute schätzt weltweite versicherte Schäden aus Katastrophen im Jahr 2021 auf 112 Mrd. USD - die bisher vierthöchste Jahressumme
EQS-News: Global insured catastrophe losses rise to USD 112 billion in 2021, the fourth highest on record, Swiss Re Institute estimates
EQS-News: Holcim completes bolt-on acquisition in the US
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
EQS-News: Swiss Re vereinbart Verkauf von elipsLife an Swiss Life International und langfristige, durch Rückversicherung gestützte Partnerschaft
EQS-News: Swiss Re agrees to sell elipsLife to Swiss Life International and to enter into a long-term partnership supported by reinsurance
EQS-News: Holcim recognized as global climate leader with CDP A rating for 2nd consecutive year
ABB Capital Markets Day 2021: Cementing Performance Culture
ABB will be hosting its Capital Markets Day today, December 7, starting 12.00 midday CET. At the event, CEO, Björn Rosengren, CFO, Timo Ihamuotila, as well as other members of the Executive
EQS-News: Holcim announces Africa's largest 3D-printed affordable housing project
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
EQS-News: Holcim Group Statement following court interview of Lafarge SA on 29 November 2021, Paris, France